Hematologic Neoplasms: Clinical Trials

80 trials for Hematologic Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

80 terminated. 80 Phase 2, 22 Phase 1, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 280Terminated 80
Phase 122Terminated 22
Phase 33Terminated 3

Follow Hematologic Neoplasms: new trials by email Literature Review of Hematologic Neoplasms trials Research Report on Hematologic Neoplasms

Trials (filtered) newest first · largest first

All 80 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study To Evaluate The Safety And Efficacy of PBCLN-010 In Combination With PBCLN-014 in Participants Receiving Allogeneic Hematopoietic Cell Transplantation
B. infantis (PBCLN-014) and Human Milk Oligosaccharides (HMO) (PBCLN-010) - Hematologic Malignancy
Phase 2TerminatedProlacta Bioscience462023-09-182024-08-19
Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.
Ruxolitinib, Mesna, Anti-thymocyte globulin (ATG) - Hematologic Malignancy, Myeloid Malignancy
Phase 2TerminatedSt. Jude Children's Research Hospital32023-03-142025-10-02
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
Fludarabine, Cyclophosphamide, Thiotepa - Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia
Phase 2TerminatedFred Hutchinson Cancer Center12022-10-062025-01-01
Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
Omacetaxine Mepesuccinate, Venetoclax - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Biphenotypic Leukemia
Phase 1 / Phase 2TerminatedM.D. Anderson Cancer Center242021-12-172025-11-03
Screening Protocol for Preliminary Eligibility Determination for Adoptive Cell Therapy Trials
Screening Platform - Neoplasms
Phase 2TerminatedGlaxoSmithKline162021-12-162024-02-05
A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma
EMB-06 - Relapsed or Refractory Multiple Myeloma
Phase 1 / Phase 2TerminatedShanghai EpimAb Biotherapeutics Co., Ltd.402021-05-202025-05-28
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
DS-1594b, Azacitidine, Cyclophosphamide - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Lymphoblastic Leukemia
Phase 1 / Phase 2TerminatedM.D. Anderson Cancer Center172021-03-252025-05-23
Thrombosomes® in Bleeding Thrombocytopenic Patients Study
Thrombosomes, Liquid Stored Platelets (LSP) - Thrombocytopenia, Hematologic Malignancy
Phase 2TerminatedCellphire Therapeutics, Inc.212021-03-052023-05-25
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
Bintrafusp Alfa, Pimasertib, Quality-of-Life Assessment - Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Phase 1 / Phase 2TerminatedM.D. Anderson Cancer Center82021-01-152026-03-18
Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis
Infliximab, Intravenous Immunoglobulin Therapy, Prednisone - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Phase 2TerminatedECOG-ACRIN Cancer Research Group12021-01-072026-09-29
Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients
Recombinant Interferon Alfa-2b, Rintatolimod - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Phase 1 / Phase 2TerminatedRoswell Park Cancer Institute42020-11-172026-01-13
Tocilizumab for Patients With Cancer and COVID-19 Disease
Tocilizumab - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Phase 2TerminatedNational Cancer Institute (NCI)12020-05-282025-02-04
Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19
BMS-986253 - Solid Tumor, Sars-CoV2
Phase 2TerminatedColumbia University432020-04-162025-05-22
Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant
Tagraxofusp-erzs - Blastic Plasmacytoid Dendritic Cell Neoplasm
Phase 2TerminatedM.D. Anderson Cancer Center32020-03-272024-07-31
Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.
MB-102, Fludarabine, Cyclophosphamide - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Phase 1 / Phase 2TerminatedMustang Bio32020-02-172024-07-22
Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies
ClinicMACs - Hematologic Malignancy
Phase 2TerminatedDana-Farber Cancer Institute22020-01-212022-05-10
Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients With Blood Diseases
Supportive Palliative Care, Clinical Management, Best Practice - Hematopoietic and Lymphoid Cell Neoplasm, Non-Neoplastic Hematologic and Lymphocytic Disorder
Phase 2 / Phase 3TerminatedFred Hutchinson Cancer Center4582019-08-152026-01-12
T Lymphocytes (LT) Expressing iCASP9 and ΔCD19 in Allogeneic Haematopoietic Transplantation.
T lymphocytes iCASP9 ΔCD19, Dimerizer drug AP1903 - Graft Versus Host Disease, Hematological Malignancies
Phase 1 / Phase 2TerminatedCentre Hospitalier Universitaire de Besancon22019-04-102025-07-09
A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM)
Temferon - Multiple Myeloma
Phase 1 / Phase 2TerminatedGenenta Science92019-03-062022-01-28
Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
Allogeneic Hematopoietic Stem Cell Transplantation, Liposome-encapsulated Daunorubicin-Cytarabine, Ruxolitinib - Essential Thrombocythemia, Myelofibrosis
Phase 1 / Phase 2TerminatedOhio State University Comprehensive Cancer Center122019-02-202026-04-24

Showing 20 of 80. Sign in to see all of them.

Narrower conditions

Myelodysplastic Syndromes (22)  ·  Leukemia, Myeloid, Acute (19)  ·  Myeloproliferative Disorders (15)  ·  Polycythemia Vera (15)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (15)  ·  Leukemia (14)  ·  Lymphoma, Non-Hodgkin (14)  ·  Multiple Myeloma (14)  ·  Primary Myelofibrosis (14)  ·  Lymphoma (11)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (10)  ·  Thrombocythemia, Essential (10)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (9)  ·  Hodgkin Disease (7)

Broader conditions

Hemic and Lymphatic Diseases (80)  ·  Neoplasms by Site (80)  ·  Hematologic Diseases (77)  ·  Neoplasms (76)  ·  Neoplasms by Histologic Type (43)  ·  Immune System Diseases (38)  ·  Immunoproliferative Disorders (36)  ·  Lymphoproliferative Disorders (36)  ·  Bone Marrow Diseases (34)  ·  Lymphatic Diseases (32)  ·  Leukemia, Lymphoid (22)  ·  Pathological Conditions, Signs and Symptoms (22)  ·  Hemorrhagic Disorders (21)  ·  Pathologic Processes (21)

Interventions

Cyclophosphamide (17)  ·  fludarabine phosphate (12)  ·  fludarabine (11)  ·  Whole-Body Irradiation (10)  ·  Busulfan (7)  ·  Stem Cell Transplantation (7)  ·  Antilymphocyte Serum (6)  ·  Cyclosporine (6)  ·  Mycophenolic Acid (6)  ·  Thiotepa (6)  ·  Radiotherapy (5)  ·  Tacrolimus (5)  ·  thymoglobulin (5)  ·  Filgrastim (4)  ·  Granulocyte Colony-Stimulating Factor (4)

Sponsors

M.D. Anderson Cancer Center (10)  ·  Fred Hutchinson Cancer Center (4)  ·  Novartis Pharmaceuticals (4)  ·  St. Jude Children's Research Hospital (4)  ·  Mayo Clinic (3)  ·  Baylor College of Medicine (2)  ·  Bellicum Pharmaceuticals (2)  ·  Bristol-Myers Squibb (2)  ·  H. Lee Moffitt Cancer Center and Research Institute (2)  ·  Incyte Corporation (2)  ·  National Cancer Institute (NCI) (2)  ·  Roswell Park Cancer Institute (2)  ·  Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (2)  ·  Alaunos Therapeutics (1)  ·  Cellphire Therapeutics, Inc. (1)

Countries

United States (72)  ·  Italy (8)  ·  Canada (5)  ·  France (5)  ·  Spain (4)  ·  Australia (3)  ·  Belgium (3)  ·  Germany (3)  ·  Israel (3)  ·  Netherlands (3)  ·  United Kingdom (3)  ·  Austria (2)  ·  Czechia (2)  ·  Belarus (1)  ·  Bulgaria (1)

Top investigators

Brandon Triplett, MD (2)  ·  Dolores Grosso, DNP, CRNP (2)  ·  George Carrum, MD (2)  ·  Neal Flomenberg, MD (2)  ·  Ruben A. Mesa, MD (2)  ·  Abhishek Maiti, MBBS (1)  ·  Amer M Beitinjaneh, MD (1)  ·  Amin Alousi, MD (1)  ·  Ana G. Antun, MD, MSc (1)  ·  Andrea Velardi, MD (1)  ·  Andrew M Yeager, MD (1)  ·  Ashok Srinivasan, MD (1)  ·  Bipin N. Savani, MD (1)  ·  Brandon M. Triplett, MD (1)

Results publications

PMID 21874061, PMID 28602585, PMID 28622623, PMID 31527168, PMID 32896301, PMID 33027528, PMID 33568350, PMID 33580980, PMID 33792630, PMID 33795208, PMID 34255353, PMID 34474640, PMID 34933330, PMID 35226739, PMID 35750419, PMID 35941212, PMID 36841758, PMID 40373381, PMID 40979071, PMID 41043099

NIH funding

P30CA015083 (3), 2009 (2), 2017 (2), 2016 (1), P01CA078902 (1), P30CA015704 (1), P30CA016056 (1), P30CA016672 (1), R01CA132197 (1), R01CA227092 (1), R21CA106177 (1), R34HL142322 (1), T32CA009515 (1), UG1CA189828 (1)